The primary role of this formulation is to provide symptomatic relief for acute discomfort. This combination is utilized across domains where additional symptomatic support is needed, particularly to address moderate acute physical pain when supportive symptom management is appropriate.

Targeted Relief for Acute, Episodic Discomfort

Panocod is relevant in contexts marked by increased discomfort or tension, generally serving as an intervention for acute symptomatic episodes. It is used when short-term symptomatic assistance is needed to help manage severe, transient discomfort, including breakthrough pain—sudden exacerbations in ongoing management.

Supportive Symptom Management for Fever and Generalized Malaise

Beyond pain, this combination is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive, specifically elevated body temperature and associated systemic body aches. It is used in situations where multiple symptoms occur together and contributes to easing the overall symptom load during periods of symptomatic strain. It is utilized for the management of these symptoms.

---

Quick Fact: Relief for Acute Pain
Primary Target	Moderate pain unresponsive to standard non-opioids.
Key Scenarios	Post-procedural discomfort, acute injury pain, breakthrough pain.
Symptom Scope	Physical pain, elevated body temperature, body aches.

Regulatory References

1. NIH MedlinePlus overview

The eligibility profile for Panocod (Acetaminophen, Codeine) is defined by strict regulatory criteria concerning age, physiological status, and metabolic risk, as documented by governmental health authorities.

Eligibility Status	Official Population Rules
Contraindicated Use	Panocod must not be used in children younger than 12 years of age. It is also contraindicated in breastfeeding women and in patients of any age known to be CYP2D6 ultra-rapid metabolizers. Use is prohibited in patients with significant respiratory depression or acute, severe bronchial asthma, and following tonsillectomy or adenoidectomy in pediatric patients (under 18 years).
Restricted or Conditional Use	Use is not recommended for adolescents (12–18 years) with compromised respiratory function (e.g., obesity or obstructive sleep apnea). The medicine requires special caution in individuals with severe hepatic (liver) or renal (kidney) impairment, necessitating careful evaluation. Use also requires caution in the elderly, debilitated patients, and those with conditions such as increased intracranial pressure or Adrenal Insufficiency.
Allowed Use	The medicine is approved for use in adults and patients older than 12 years of age for acute moderate pain when other non-opioid analgesics alone are insufficient.

The combination of acetaminophen and codeine in Panocod can interact with various other medicines and substances. It is essential to inform your healthcare provider of all prescription, non-prescription, herbal, and vitamin supplements you are taking to prevent serious adverse effects.

Increased Risk of Sedation and Respiratory Depression

Concomitant use of Panocod with other Central Nervous System (CNS) depressants significantly increases the risk of profound sedation, severe respiratory depression, coma, and death. Avoid taking Panocod with:

• Alcohol
• Benzodiazepines and other sedatives or hypnotics (e.g., those for sleep or anxiety)
• Other Opioid Medications (e.g., for pain or cough)
• Muscle Relaxants
• Antihistamines that cause drowsiness

Interactions Affecting Codeine Metabolism

Codeine is metabolized in the liver by certain enzymes (CYP450). Medications that affect these enzymes can alter codeine's effects:

Type of Interaction	Effect	Examples of Drug Classes
Enzyme Inhibitors (e.g., CYP2D6, CYP3A4)	May increase codeine/morphine levels, potentially increasing side effects and toxicity.	Certain Antidepressants, Antifungals, Macrolide Antibiotics
Enzyme Inducers (e.g., CYP3A4)	May decrease codeine/morphine levels, potentially reducing efficacy and causing withdrawal symptoms.	Certain Seizure Medications

Acetaminophen-Specific Interactions

• Other Acetaminophen-Containing Products: Do not take Panocod with other products containing acetaminophen (e.g., some cold and flu remedies), as this increases the risk of liver damage (hepatotoxicity). The maximum safe daily dose of acetaminophen must not be exceeded.
• Anticoagulants: Acetaminophen, particularly with prolonged use at higher doses, may enhance the effect of certain blood thinners like warfarin, requiring closer monitoring.

How Panocod (Acetaminophen, Codeine) Works

Panocod combines two agents to produce distinct yet complementary biological effects by targeting both central and peripheral signaling pathways.

Regulation of Central Afferent Signaling via mu-Opioid Receptor Agonism

Codeine, an opioid prodrug, is metabolized to morphine, which acts as an agonist at mu-opioid receptors ( MOR) predominantly within the central nervous system, including the spinal cord and brain. Activation of the MOR initiates signaling sequences that modulate neurotransmitter release and induce neuronal hyperpolarization. These early molecular steps reshape systemic physiological outcomes by attenuating central neuronal excitability and modulating afferent nociceptive signaling within the CNS.

Modulation of Mediator Synthesis via COX Inhibition

Acetaminophen (paracetamol) is believed to exert its action primarily through the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2 and a potential COX-3 variant, mostly in the central nervous system. This activity supports the regulation of processes driven by distinct signaling patterns by reducing the concentration of specific inflammatory mediators like prostaglandins. This action alters set-point regulation within targeted pathways, thereby influencing the local biochemical environment that governs thermoregulation and peripheral afferent sensitivity.

Administration Guidelines

This combination product is intended for oral administration, typically provided as a tablet, capsule, or solution. The medicine is used for intermittent application, administered as needed for relief. The standard adult dosing regimen is generally one to two units per administration.

Dosing Frequency and Limits

Standard instructions specify a strict minimum time interval of at least four to six hours between administrations. A critical constraint on use is the total amount of the acetaminophen component: the combined dose from this product and any other sources must not exceed 4,000 mg (4 g) within a 24-hour period. Because of this limitation, guidelines advise against taking this product with any other medicine containing acetaminophen.

Contextual and Time-Limited Use

The medicine may be taken with or without food. If the product is a soluble tablet, it is fully dissolved in water prior to ingestion. Treatment should be for the shortest duration possible that is consistent with the therapeutic need. For instance, short-term use for acute pain is often limited to a few days. If the medicine has been taken regularly, discontinuation is achieved through gradual tapering rather than abrupt cessation.

Population-Specific Use Rules

Administration guidelines include explicit conditions for specific populations. The medicine is contraindicated in children younger than 12 years of age and in adolescents under 18 years following tonsillectomy or adenoidectomy. Furthermore, patients with reduced renal or hepatic function often require an extension of the minimum time interval between doses to prevent accumulation of the components.

Research evidence / Overview of studies for Panocod (Acetaminophen,Codeine)

Evidence from Trials for Acute, Moderate Physical Pain

Research has explored this fixed-dose combination in trials assessing short-term or episodic symptom patterns. These studies are typically controlled trials that monitor responses over defined time intervals, such as immediately following a surgery or a dental procedure. In these controlled settings, research examined outcomes related to physical discomfort over short periods.

The findings describe patterns observed in the studies, particularly in settings where symptoms are acute and disruptive. Research highlights changes measured during the study period, which contributes to understanding short-term findings. However, it is important to understand that the results apply only to the populations studied, and comparative evidence against a full range of alternative treatments is sometimes lacking. These studies contribute to the broader evidence landscape.

Research Findings for Persistent (Chronic) Pain

Limited research has explored this combination in conditions characterized by fluctuating or episodic manifestations that may involve persistent discomfort. In these scenarios, studies were conducted during periods of increased symptom activity and focused on outcomes reflecting daily functioning or activity level.

In these contexts, the evidence contributes to understanding general symptom patterns, but overall findings were mixed regarding the sustained metrics for patient-reported outcomes describing perceived discomfort. Because the evidence is limited in this area, certainty remains low for outcomes beyond short study durations. The data show patterns related to short-term changes within these conditions, but the evidence highlights what is known — and what is still uncertain — about longer-duration use.

Limitations in Long-Term Studies and Follow-up

A clear limitation across the body of research for this combination is the duration of observation. Most studies are designed for short-term use, meaning the follow-up durations were limited. Consequently, there is limited information for long-term outcomes regarding the use of this combination.

Because the studies primarily observed responses over defined time intervals measured in hours or days, the long-term effects are not fully established. This means that data are still emerging, and research is ongoing to characterize the patterns observed after repeated exposure over longer periods.

Key Studies & References

1. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update (CPIC)
2. Codeine for cough or cold in children Art. 31 - Assessment report for publication (EMA PRAC)
3. Safety and efficacy of the combination Acetaminophen-Codeine in the treatment of pain of different origin
4. WHO Model List of Essential Medicines (23rd list, 2023)

Common questions about Panocod (Acetaminophen,Codeine) (FAQ)

Q: Is Panocod always a prescription-only medicine?

A: Official drug labels generally classify Panocod, which contains the narcotic analgesic codeine, as a prescription-only controlled substance in many regions. However, regulations regarding lower-dose codeine combination products can vary by country.

Q: How quickly does Panocod usually start working after taking it?

A: According to the official prescribing information, the pain-relieving effect of the codeine component typically reaches its maximum level, or peak, within two hours after the medicine is taken by mouth. However, individual responses and the onset of effect can vary.

Q: What is the expected duration of pain relief from one dose of Panocod?

A: The pain-relieving effect of the codeine component at therapeutic doses typically lasts between four and six hours. Official documents indicate that this duration aligns with the regulated minimum interval between doses.

Q: Can Panocod cause chronic constipation?

A: Constipation is listed in official documents as a commonly reported side effect. Codeine, like other opioids, works by slowing down the digestive system. Regulatory information on opioid analgesics notes that chronic or long-term use has been associated with serious bowel conditions in some patients.

Q: Is it necessary to store Panocod in a highly secure place?

A: Due to the potential for abuse and misuse associated with the opioid component, regulatory guidance advises that Panocod be stored securely. This means keeping it out of the sight and reach of children and in a location that is not accessible to visitors or others.

Q: What are the risks of using Panocod during pregnancy, especially near delivery?

A: Official information advises that if Panocod is taken regularly during pregnancy, the baby may experience neonatal opioid withdrawal syndrome (NOWS) after birth. This is a serious condition noted in regulatory warnings that may require specialized medical attention at the time of birth.

Q: What is the main concern for elderly patients who are prescribed Panocod?

A: Regulatory warnings highlight the risk of a severe reduction in breathing, known as respiratory depression, for elderly patients using this class of medication. The risk of adverse reactions is generally greater in older patients due to potential decreased organ function.

Q: Why is codeine metabolism different in some ethnic groups?

A: Codeine is converted into its active form (morphine) by the CYP2D6 enzyme in the body. The prevalence of the ultra-rapid metabolizer gene for this enzyme varies widely among ethnic populations. This variation is recognized by regulators as affecting the expected effectiveness and potential safety risks across different populations.

Q: How is Panocod different from taking a single ingredient pain reliever?

A: Panocod is a combination analgesic that contains both a non-opioid pain reliever, acetaminophen, and a narcotic analgesic, codeine. This dual-action formulation is intended for pain relief when a single non-opioid medication is not sufficient to manage the discomfort.

Q: Is Panocod used for short-term pain relief only?

A: Official guidelines advise that treatment with Panocod should be for the shortest duration possible that is consistent with the patient's therapeutic need. Long-term or repeated use carries known risks of addiction, abuse, and dependence.

Q: Is it normal if Panocod does not seem to relieve pain right away?

A: The full peak analgesic effect of the codeine component is generally not reached until about two hours after taking the medicine. Variability in the body's ability to metabolize codeine can also influence the time and degree of effectiveness in different individuals.

Q: Why do some individuals experience different levels of effectiveness from the codeine component?

A: Codeine is metabolized into the active compound, morphine, by the CYP2D6 enzyme. Individuals are classified as ultra-rapid, extensive, or poor metabolizers depending on their genetic makeup. This variation in how quickly the body performs this conversion directly results in different levels of pain relief.

Q: What kind of breathing changes are associated with taking Panocod?

A: The life-threatening risk of respiratory depression associated with the codeine component can involve breathing becoming unusually slow, shallow, or difficult. This kind of change is noted in official documents as a serious sign that warrants prompt medical evaluation.

Q: Does Panocod affect the digestive system besides causing constipation?

A: Nausea and vomiting are commonly reported side effects. Additionally, codeine carries a risk of conditions involving a blockage or narrowing of the stomach or intestines, such as paralytic ileus.

Q: Are there any known severe or rare skin reactions linked to the acetaminophen component?

A: The acetaminophen component has been associated with rare but severe skin reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP). Regulatory warnings note these reactions can be fatal.

Q: Can Panocod cause a feeling of confusion or mental fog?

A: Yes, regulatory documents list central nervous system effects such as dizziness, lightheadedness, and mild confusion as possible adverse reactions. This is particularly noted when the medicine is used with other medications that cause sedation.

Q: Is a dry mouth a frequent side effect of Panocod?

A: Although it is not always listed among the most common adverse reactions in all prescribing information, dry mouth is a reported symptom associated with the use of opioid-containing medications.

Q: What should a user know about changes in appetite while using Panocod?

A: Official regulatory information lists loss of appetite as a symptom that may be associated with two of the serious risks related to the drug’s components: liver injury or low adrenal gland function. Official documents list these as serious symptoms that warrant medical attention.

Q: What are the typical signs of physical withdrawal when stopping Panocod?

A: Official guidelines recommend that if the medicine has been taken regularly, discontinuation should be achieved through gradual tapering to mitigate the possibility of withdrawal signs. These physical signs can include agitation, confusion, sweating, shivering, severe muscle stiffness, and diarrhea.

Q: Can long-term use of Panocod affect hormone levels or fertility?

A: Opioids, including the codeine component, are known to inhibit the secretion of certain hormones. Regulatory information notes that long-term use of this medication may decrease fertility in both men and women.

Q: What is the risk of overdose when Panocod is taken exactly as described in official sources?

A: Official boxed warnings state that accidental ingestion of even one dose of this combination product, particularly by a child, can result in a fatal overdose. Secure storage is necessary to mitigate this risk.

Q: Are there specific over-the-counter cold or flu medicines that should be checked for interactions with Panocod?

A: Due to the risk of exceeding the maximum safe daily dose, official guidance advises checking all cold and flu medicines, as many contain acetaminophen (paracetamol). Taking Panocod with other acetaminophen products can significantly increase the risk of liver damage.

Q: Are there any known food or herbal interactions with Panocod?

A: Official warnings advise caution or avoidance of certain herbal products, such as St. John's wort and tryptophan, as well as grapefruit or grapefruit juice. These substances may interfere with the metabolism of the codeine component.

Q: Is it possible for Panocod to interact with certain migraine medicines?

A: The opioid component of Panocod is noted in regulatory warnings as potentially interacting with serotonergic drugs, which include some common migraine medicines (triptans). Regulatory warnings note that if these medications are used together, the possibility of serotonin syndrome should be considered.

Q: What medical conditions, other than liver or kidney issues, are noted in official warnings for Panocod use?

A: Official warnings note that conditions requiring caution include increased pressure in the skull (increased intracranial pressure), low adrenal gland function, thyroid or pancreatic disease, and a history of seizures.

Q: What is the difference between Panocod and co-codamol?

A: Co-codamol is a widely recognized general name for the fixed-dose combination of acetaminophen (paracetamol) and codeine. Panocod contains this identical combination of active ingredients and is used for the same pain relief purpose.

Q: Does Panocod help with a cough or only with pain?

A: While the primary approved use is for the management of pain, codeine is an ingredient that has historically been used to reduce coughing. It is often found in combination with other medications used for cough and cold symptoms.

Q: Can people with kidney disease safely use Panocod?

A: Patients with severe kidney (renal) impairment typically require a longer time interval between doses to prevent the accumulation of the drug’s components. In cases of kidney disease that are not severe, official documents still suggest careful evaluation before use.

The medicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted to 15 C to 30 C.

• The product must be kept in its proper labeled container and stored away from excess heat and moisture. Do not freeze the medicine.
• Due to the risks associated with the opioid component, Acetaminophen and Codeine must be stored securely, out of the sight and reach of children, and in a location not accessible to visitors or others.
• Disposal: The preferred method is to utilize a drug take-back program or an authorized collector. If no take-back option is available, the product must be mixed with an unappealing substance (such as dirt or coffee grounds) and sealed in a container before being discarded in the household trash. Disposal must conform to local regulations.